Paula J Fonseca
Overview
Explore the profile of Paula J Fonseca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garrido M, Fonseca P, Vieitez J, Frunza M, Lacave A
Expert Rev Anticancer Ther
. 2014 Jun;
14(8):887-900.
PMID: 24953238
Chemotherapy prolongs survival in advanced gastric cancer (AGC). The challenges involved in this procedure are providing a framework to aid in determining the best single or combined chemotherapy protocols for...
2.
Fonseca P, Uriol E, Galvan J, Alvarez C, Perez Q, Villanueva N, et al.
Case Rep Oncol
. 2013 Sep;
6(2):441-9.
PMID: 24019785
Treatment options for patients with high-grade pancreatic neuroendocrine tumors (pNET) are limited, especially for those with progressive disease and for those who experience treatment failure. Everolimus, an oral inhibitor of...
3.
Galvan J, Astudillo A, Vallina A, Fonseca P, Gomez-Izquierdo L, Garcia-Carbonero R, et al.
Am J Clin Pathol
. 2013 Jun;
140(1):61-72.
PMID: 23765535
Objectives: To elucidate the role of epithelial-mesenchymal transition markers in gastroenteropancreatic neuroendocrine tumors (GEP NETs) and the potential usefulness in their clinical management. Methods: One hundred ten GEP NET paraffin-embedded...
4.
Lopez C, Esteban E, Berros J, Pardo P, Astudillo A, Izquierdo M, et al.
Clin Genitourin Cancer
. 2012 Sep;
10(4):262-70.
PMID: 22959659
Background: The purpose of this study was to evaluate prognostic factors in patients with RCC. Materials And Methods: The expression of several biomarkers were measured by immunohistochemistry (IHC), together with...
5.
Lopez C, Esteban E, Astudillo A, Pardo P, Berros J, Izquierdo M, et al.
Invest New Drugs
. 2012 May;
30(6):2443-9.
PMID: 22644070
Introduction: The analysis of predictive factors of response may aid in predicting which patients with advanced renal cell carcinoma (RCC) would be good candidates for systemic treatments. Materials And Methods:...
6.
Bayo J, Fonseca P, Hernando S, Servitja S, Calvo A, Falagan S, et al.
Clin Transl Oncol
. 2012 May;
14(6):413-22.
PMID: 22634529
Chemotherapy-induced nausea and vomiting (CINV) is a major determinant of quality of life in cancer patients. In addition, the perceptions that oncology professionals have about CINV quite often do not...
7.
Crespo G, Sierra M, Losa R, Berros J, Villanueva N, Fra J, et al.
Int J Gynecol Cancer
. 2011 Mar;
21(3):478-85.
PMID: 21436695
Introduction: Pegylated liposomal doxorubicin (PLD) is currently the reference treatment for platinum-resistant ovarian cancer. The combination of PLD and gemcitabine and the administration of gemcitabine at a fixed dose rate...
8.
Muriel C, Esteban E, Corral N, Fonseca P, Luque M, Berros J, et al.
Clin Transl Oncol
. 2010 Aug;
12(8):562-7.
PMID: 20709657
Introduction: For nearly the past two decades, cytokines (CKs) have been the only systemic treatment option available for advanced renal cell carcinoma (RCC). In recent years, tyrosine kinase inhibitors (TKIs)...